enGene Therapeutics Inc.
ENGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeenGene Therapeutics Inc. enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. At a $104.5M market cap, enGene Therapeutics Inc. ranks as a micro-cap company within healthcare. The company develops genetic medicines to help patients suffering from bladder cancer.
Market Cap
$104.5M
Beta
-0.28
P/E (TTM)
—
P/E (Fwd)
-1.03
EPS (TTM)
$-2.01
EPS (Fwd)
$-1.51
ROE
-60.5%
ROA
-32.0%
Cash
$266.3M
Total Debt
$33.3M
Free CF
-$60.9M
52W Change
-80.4%
Annual Financials
Cash vs Debt
Where ENGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ENGN finished 49.68% below its 150-day moving average ($3.14) and 66.24% below its 200-day moving average ($4.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENGN overbought or oversold?
At the October 20, 2026 close, ENGN's RSI(14) was 28.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
enGene Therapeutics Inc. holds $266.3M in cash against $33.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$60.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -60.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, enGene Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence enGene Therapeutics Inc.'s trajectory.